C. Jiménez

Publications155
h-index29
Citations2,974
Highly Influential Citations128
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Pacak
  • 725 Publications, 30,841 Citations
  • M. Schlumberger
  • 609 Publications, 47,158 Citations
  • R. Gagel
  • 313 Publications, 21,690 Citations
  • M. Habra
  • 143 Publications, 3,631 Citations
  • Publications
  • Influence
Parathyroid carcinoma: A 22‐year experience
Because parathyroid carcinoma is rare, clear consensus is not available regarding the optimal management of patients with this condition. Treatment strategies generally derive from clinical and… Expand
  • 171
  • 16
  • PDF
Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
CONTEXT Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from… Expand
  • 242
  • 10
  • PDF
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
OBJECTIVE Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. Herein, we describe the clinical features and outcomes for a large series of ACC patients. DESIGN AND METHODS… Expand
  • 133
  • 8
  • PDF
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
CONTEXT Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES The primary… Expand
  • 136
  • 6
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
CONTEXT Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a… Expand
  • 74
  • 6
Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
CONTEXT Bone metastases (BM) can cause severe pain, spinal cord compression, pathological fractures, and/or hypercalcemia. These skeletal-related events (SREs) may cause immobilization, loss of… Expand
  • 61
  • 5
Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
CONTEXT von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs. EVIDENCE ACQUISITION We present a patient with von Hippel-Lindau disease with multiple renal and… Expand
  • 116
  • 4
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas
The objective of this study was to evaluate the clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic paragangliomas by assessing reductions in… Expand
  • 90
  • 4
Posterior Retroperitoneoscopic Adrenalectomy: Preferred Technique for Removal of Benign Tumors and Isolated Metastases
Objective:Posterior retroperitoneoscopic adrenalectomy (PRA) is a minimally invasive approach to removal of the adrenal gland. This anatomically direct approach, popularized by Walz, minimizes… Expand
  • 73
  • 4
  • PDF
Management of medullary thyroid carcinoma.
Medullary thyroid carcinoma (MTC) is responsible for 13.4% of the total deaths attributable to thyroid cancer in human beings and research on MTC over the last 40 years has identified the RET… Expand
  • 82
  • 4